[Chemotherapy of human echinococcosis with mebendazole (Vermox): preliminary clinical results].
Two patients with inoperable multiple Echinococcus granulosus infections involving the lungs and the liver (one patient) were treated with the following daily doses of mebendazole (Vermox): 3 days 1000 mg, 3 days 1500 mg, the following 3 months 30-40 mg/kg body weight. One of the patients had been treated before with mebendazole in similar doses for 3 periods of 5-6 weeks each. The patients received the drug as 500 mg tablets divided into 3 daily doses after meals. After termination of treatment a distinct regression of lung cysts was demonstrable in both patients, with the exception of one cyst. The liver cyst in one of the patients had also decreased in size. About 8 months after therapy signs of reactivation of lung cysts were observed in one patient, and a new course of mebendazole treatment was therefore started.
D000328:Adult; D001562:Benzimidazoles / Q000627:therapeutic use*; D004341:Drug Evaluation; D004443:Echinococcosis / Q000188:drug therapy*; D004444:Echinococcosis, Hepatic / Q000188:drug therapy; D004445:Echinococcosis, Pulmonary / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D008463:Mebendazole / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged
D001562:Benzimidazoles; D008463:Mebendazole
Chemotherapie der Echinokokkose des Menschen mit Mebendazol (Vermox): Vorläufige klinische Erfahrungen.